News

Shandong Xiwang Pharmaceutical Co., Ltd.: Driving High-Quality Development Through Technological Innovation
Shandong Xiwang Pharmaceutical Co., Ltd.: Driving High-Quality Development Through Technological Innovation

Shandong Xiwang Pharmaceutical Co., Ltd. was awarded the title of "Top Ten Innovative Enterprises in China's Pharmaceutical Industry" at the 2025 China Pharmaceutical Innovation and Development Conference, a high recognition of the company's technological innovation achievements in the pharmaceutical field. As a core enterprise of the Xiwang Group's pharmaceutical sector, Shandong Xiwang Pharmaceutical has always adhered to the development philosophy of "innovation-driven, quality-first," achieving a series of significant breakthroughs in the research and development and production of active pharmaceutical ingredients (APIs).Shandong Xiwang Pharmaceutical possesses a national-level enterprise technology center and a postdoctoral research station, establishing a comprehensive innovation system. Its annual R&D investment accounts for over 8% of its sales revenue. In recent years, the company has achieved numerous innovative results in the fields of glucose derivatives and pharmaceutical excipients. Among them, the "High-purity Anhydrous Glucose Preparation Technology" won the first prize of Shandong Provincial Science and Technology Progress Award, and the "Pharmaceutical Maltodextrin Industrialization Project" was included in the National Key New Product Plan.In terms of quality control, Shandong Xiwang Pharmaceutical Co., Ltd. has established a full-chain quality traceability system and has passed ISO9001, ISO14001, ISO45001, HACCP, and GMP certifications, achieving internationally advanced product quality levels. The company's glucose raw materials, fructose, and other products have passed multiple authoritative international certifications, including the US FDA, EU CEP, and Japanese PMDA, and are exported to more than 60 countries and regions worldwide.The chairman of Shandong Xiwang Pharmaceutical Co., Ltd. stated, "Shandong Xiwang Pharmaceutical Co., Ltd. will take this award as an opportunity to continue increasing R&D investment, accelerate the transformation of innovative achievements, and contribute Xiwang's strength to the high-quality development of the pharmaceutical industry." In the future, the company plans to expand into the biopharmaceutical field, developing innovative drugs with independent intellectual property rights, and achieving industrial upgrading from raw materials to finished products. CONTACT INFORMATIONWebsite:https://www.xiwang-pharmaceutical.com/Phone:+8615371019725Email:sales7@boxa-chem.com

Xiwang Pharmaceutical Co., Ltd.'s glucose raw material has passed EU GMP recertification.
Xiwang Pharmaceutical Co., Ltd.'s glucose raw material has passed EU GMP recertification.

Xiwang Pharmaceutical Co., Ltd. announced that its core product, glucose API, has successfully passed the EU GMP recertification. This is another significant milestone for the company following its initial certification in 2020, signifying that Xiwang Pharmaceutical's quality management system and product quality continue to meet the highest international standards, laying a solid foundation for the company to further expand into the high-end European market. As a leading enterprise in the domestic starch sugar API industry, Xiwang Pharmaceutical has focused on the R&D and production of glucose series products for over 20 years. With an annual production capacity of 300,000 tons of glucose API, it is one of the world's largest glucose production bases. The company's glucose products cover multiple varieties, including anhydrous glucose, monohydrate glucose, and oral glucose, with purity ranging from 99.5% to 99.9%, and are widely used in pharmaceuticals, food, and chemical industries. The glucose API that passed the EU GMP recertification this time adopts internationally advanced fully enclosed production technology, achieving full-chain quality control from corn raw materials to finished products. Key quality indicators all meet or exceed European Pharmacopoeia standards. The quality manager of Xiwang Pharmaceutical Co., Ltd. stated, "The successful EU GMP recertification is a high recognition of the product quality and production management system of Xiwang Pharmaceutical Co., Ltd. The company has always adhered to the principle of 'quality first, customer foremost,' establishing a comprehensive quality traceability system and passing ISO9001, ISO14001, ISO45001, HACCP, and GMP certifications to ensure that every batch of products meets domestic and international regulatory requirements." It is understood that Xiwang Pharmaceutical's glucose raw materials have been exported to more than 50 countries and regions worldwide, establishing a high-quality image for "Made in China" in the international market. This successful certification not only enhances Xiwang Pharmaceutical Co., Ltd.'s position in the global pharmaceutical supply chain but also provides an important reference for the Chinese glucose raw material industry to participate in international competition, demonstrating the strong capabilities of Chinese pharmaceutical manufacturing. In the future, Xiwang Pharmaceutical will continue to increase R&D investment, optimize its product structure, develop more high-value-added glucose derivative products, and further expand its international market reach.

Shandong Xiwang Pharmaceutical Co., Ltd. has been recognized as a High-tech Enterprise for five consecutive terms.
Shandong Xiwang Pharmaceutical Co., Ltd. has been recognized as a High-tech Enterprise for five consecutive terms.

Shandong Xiwang Pharmaceutical Co., Ltd. has been successfully listed in the "Supplementary Filing List of High-tech Enterprises Certified and Registered by Shandong Provincial Certification Agencies." This marks the fifth consecutive time the company has passed the high-tech enterprise certification since its initial recognition in 2011, fully demonstrating its leading position in technological innovation.As a core enterprise in the pharmaceutical sector of Xiwang Group, Shandong Xiwang Pharmaceutical has always adhered to the development philosophy of "innovation-driven, quality-first," achieving a series of significant breakthroughs in the research and production of active pharmaceutical ingredients (APIs). The company possesses a national-level enterprise technology center and a postdoctoral research station, establishing a comprehensive innovation system, with annual R&D investment exceeding 8% of sales revenue. In recent years, the company has achieved numerous innovative results in glucose derivatives and pharmaceutical excipients, among which the "High-purity Anhydrous Glucose Preparation Technology" won the first prize of Shandong Provincial Science and Technology Progress Award, and the "Pharmaceutical Maltodextrin Industrialization Project" was included in the National Key New Product Plan.In terms of products, Shandong Xiwang Pharmaceutical Co., Ltd. currently holds five drug production approval numbers. Its pharmaceutical glucose production scale and market share rank first in China, exceeding 85%. The company's pharmaceutical glucose not only dominates the domestic market but is also exported to over 60 countries and regions worldwide, making it a preferred supplier for many internationally renowned pharmaceutical companies. Furthermore, the company is actively expanding its pharmaceutical excipient business; its maltodextrin, corn starch, and other products have been approved by the National Medical Products Administration and are widely used in the production of various dosage forms of pharmaceuticals, including tablets and capsules.The Chairman of Shandong Xiwang Pharmaceutical Co., Ltd. stated, "Being recognized as a high-tech enterprise for five consecutive terms is a full affirmation of Shandong Xiwang Pharmaceutical Co., Ltd.'s technological strength and R&D level. In the future, the company will continue to increase R&D investment, accelerate the transformation of innovative achievements, and contribute Xiwang's strength to the high-quality development of the pharmaceutical industry."

Xiwang Pharmaceutical Co., Ltd. China
Xiwang Pharmaceutical Co., Ltd. China

At the recently concluded CPHI 2026 Global Pharmaceutical Ingredients Exhibition (Frankfurt), Xiwang Pharmaceutical Co., Ltd. China, representing the Chinese pharmaceutical raw material industry, made a brilliant appearance. With its high-quality glucose raw materials and strong technological capabilities, it attracted attention from customers in over 100 countries and regions worldwide, securing over US$50 million in intended orders on-site, setting a new record.CPHI, one of the world's most influential pharmaceutical industry exhibitions, is an important platform for companies to showcase their strength and expand into international markets. Xiwang Pharmaceutical Co., Ltd. China's participation in this exhibition focused on showcasing its core product—high-purity glucose raw materials—as well as its latest glucose derivatives, including sodium gluconate and maltodextrin. These products, with their superior quality, stable performance, and competitive pricing, won high recognition from international customers.The head of Xiwang Pharmaceutical's International Business Department stated, "As China's largest pharmaceutical glucose production base, Xiwang Pharmaceutical Co., Ltd. China is committed to providing high-quality products and services to global customers. In recent years, the company has actively responded to the national 'Belt and Road' initiative, accelerating its international expansion. Its products have been exported to more than 50 countries and regions worldwide, establishing a positive image for 'Made in China' in the international market. This exhibition not only showcases the company's product advantages but also provides an opportunity to build closer cooperative relationships with international customers." During the exhibition, Xiwang Pharmaceutical Co., Ltd. China also reached strategic cooperation agreements with several internationally renowned pharmaceutical companies, including a long-term supply agreement with a large German pharmaceutical group to provide high-quality glucose raw materials for antibiotic production; and a collaboration with a French biopharmaceutical company to develop novel pharmaceutical excipients. These collaborations will further enhance Xiwang Pharmaceutical's influence in the international market and propel China's pharmaceutical raw material industry to the center stage globally. CONTACT INFORMATIONWebsite:https://www.xiwang-pharmaceutical.com/Phone:+8615371019725Email:sales7@boxa-chem.com

Shandong Xiwang Sugar: Corn Deep Processing Industrial Cluster Reaches New Heights
Shandong Xiwang Sugar: Corn Deep Processing Industrial Cluster Reaches New Heights

Shandong Xiwang Sugar Co., Ltd. was awarded the title of "Top Ten Enterprises in China's Light Industry Fermentation Industry" at the 2026 China Light Industry Fermentation Industry Annual Conference. This is a high recognition of the company's outstanding contributions to the field of corn deep processing, signifying that Xiwang Sugar has become a benchmark enterprise in China's fermentation industry, leading the industry's high-quality development.Shandong Xiwang Sugar Co., Ltd. is a subsidiary of Xiwang Group Co., Ltd., and is a large-scale national agricultural and sideline product processing enterprise integrating corn acquisition, deep processing, product research and development, production, sales, and technical services. The company processes 3 million tons of corn annually, boasting the largest single-region, intensive scale in China. It possesses a corn fructose production line with core technologies and large-scale production in China, as well as a globally leading monomeric starch sugar production line. Its main products include fructose, pharmaceutical glucose, edible glucose, sodium gluconate, maltodextrin, and corn starch, which are widely used in the pharmaceutical, food, fermentation, chemical, and feed industries.In terms of product innovation, Shandong Xiwang Sugar has continuously increased its R&D investment, developing a series of high value-added products, including crystalline fructose, oligosaccharides, and solid fructose-glucose. Its annual production of crystalline fructose is 50,000 tons, holding a 60% market share in China, while its annual production of pharmaceutical glucose is 1.8 million tons, holding an 85% market share in China. The company also actively promotes green production, adopting advanced energy-saving and emission-reduction technologies to achieve resource recycling. It has been recognized as a national-level green factory and a Shandong Province manufacturing single-item champion enterprise.The General Manager of Shandong Xiwang Sugar stated, "Winning the title of 'Top Ten Enterprises in China's Light Industry Fermentation Sector' is a full affirmation of Shandong Xiwang Sugar's comprehensive strength. The company will take this opportunity to further enhance its core competitiveness, accelerate industrial upgrading, and make greater contributions to the development of China's corn deep processing industry." In the future, Shandong Xiwang Sugar will also expand into the field of bio-based materials, exploring new growth points in the corn deep processing industry and propelling the company towards becoming a world-class enterprise.

Shandong Xiwang Group Co., Ltd.Deeply involved in the corn deep processing industry
Shandong Xiwang Group Co., Ltd.Deeply involved in the corn deep processing industry

Shandong Xiwang Group Co., Ltd. was awarded the title of "Benchmark Enterprise for High-Quality Development of China's Manufacturing Industry" at the China Enterprise Development Forum. This award is a high recognition of the company's more than 30 years of focus on its two main businesses, corn deep processing and special steel, and its commitment to innovation-driven development. It signifies that Xiwang Group has become a significant force leading the transformation and upgrading of China's manufacturing industry.Founded in 1986 and headquartered in Xiwang Industrial Park, Zouping City, Shandong Province, Shandong Xiwang Group Co., Ltd. is a large-scale national enterprise group with corn deep processing and special steel as its main businesses, and investments in sports nutrition, logistics, finance, and international trade. The company holds controlling stakes in three listed companies: Xiwang Food, Xiwang Special Steel, and Xiwang Real Estate, forming the only large-scale, fully integrated corn deep processing industrial chain and high-end special steel production system in China, earning it the reputation of "China's Sugar Capital" and "China's Corn Oil City."In the corn deep processing sector, Shandong Xiwang Group Co., Ltd. processes 3 million tons of corn annually, making it the largest intensive corn deep processing base in China. It boasts a globally leading monomeric starch sugar production line and a domestically developed, large-scale corn fructose production line with core technology. The company's edible glucose, pharmaceutical glucose, and crystalline fructose products all hold over 85% of the domestic market share, with crystalline fructose alone reaching 50,000 tons annually and a 60% domestic market share. These products are widely used in the pharmaceutical, food, fermentation, chemical, and feed industries, and are exported to over 50 countries and regions worldwide, establishing a high-quality image for "Made in China" in the international market.The special steel sector, another core business of Shandong Xiwang Group Co., Ltd., has an annual capacity of 3 million tons and possesses a complete production process from ironmaking and steelmaking to secondary metallurgy, continuous casting, and rolling. The company's high-end rare earth special steel materials are widely used in high-speed rail, automobiles, shipbuilding, wind power, bearings, and petrochemicals, providing crucial material support for the country's major equipment manufacturing. In recent years, the company has increased its R&D investment, developing a series of high-value-added products, including high-strength automotive steel and wind power-specific steel, continuously enhancing its market competitiveness.Shandong Xiwang Group Co., Ltd. consistently adheres to the two major development strategies of "expanding the grain and oil industry and refining special steel production," integrating its corporate development into national strategies and striving to build two national-level bases: the "National Grain and Oil Innovation Development Demonstration Base" and the "National High-end Rare Earth Special Steel New Material Support Base." The company possesses a national-level enterprise technology center and a postdoctoral research station, with annual R&D investment exceeding 8% of sales revenue. It has achieved numerous innovative results in glucose derivatives, pharmaceutical excipients, and high-end special steel, among which the "High-purity anhydrous glucose preparation technology" won the first prize of Shandong Provincial Science and Technology Progress Award.In terms of green development, Shandong Xiwang Group Co., Ltd. actively promotes energy-saving and emission-reduction technological transformation, achieving resource recycling and has been recognized as a national-level green factory and a Shandong Provincial Manufacturing Single Champion Enterprise. The company has established a full-chain quality traceability system and has passed ISO9001, ISO14001, ISO45001, HACCP, and GMP certifications, ensuring that every batch of products meets domestic and international regulatory requirements.The Chairman of Shandong Xiwang Group Co., Ltd. stated, "Being awarded the title of 'Benchmark Enterprise for High-Quality Development of China's Manufacturing Industry' is a full affirmation of Xiwang Group's comprehensive strength. The company will take this opportunity to continue increasing R&D investment, accelerate the transformation of innovative achievements, and contribute Xiwang's strength to the high-quality development of China's manufacturing industry." In the future, Xiwang Group will continue to focus on its two main businesses, promote industrial upgrading, and achieve a transformation from scale expansion to quality and efficiency-oriented development, striving to build a world-class enterprise.